NCT06088654 2026-04-14
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Innate Pharma
Phase 1/2 Terminated
Clinical Trials
184 trialsNCT02681302 2026-04-03
CPIT001
Hackensack Meridian Health
Phase 1/2 Terminated
NCT03983668 2026-03-30
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
Phase 1/2 Terminated
NCT03590574 2026-03-16
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Autolus Limited
Phase 1/2 Terminated
NCT05721222 2026-03-04
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Genmab
Phase 1/2 Terminated
NCT03953326 2026-02-27
HeartPhone Cancer Survivors Trial 2019
Penn State University
Phase 1/2 Terminated
NCT04362007 2026-02-25
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Otsuka Pharmaceutical Co., Ltd.
Phase 1/2 Terminated
NCT04809467 2026-02-04
topMIND
Incyte Corporation
Phase 1/2 Terminated
NCT04425070 2026-01-05
TOUCH
Antengene Corporation
Phase 1/2 Terminated
NCT06106841 2025-12-30
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Terminated
NCT04824794 2025-12-22
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Phase 1/2 Terminated
NCT05086315 2025-12-15
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi
Phase 1/2 Terminated
NCT05317936 2025-12-15
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03698552 2025-12-12
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00776373 2025-11-05
UPCC 25406
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT04035434 2025-10-24
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04541017 2025-10-16
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT06018129 2025-09-25
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Genmab
Phase 1/2 Terminated
NCT03769181 2025-09-23
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Sanofi
Phase 1/2 Terminated
NCT05626322 2025-09-05
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pfizer
Phase 1/2 Terminated
NCT05032183 2025-08-11
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03287817 2025-07-14
ALEXANDER
Autolus Limited
Phase 1/2 Terminated
NCT03013491 2025-06-17
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
CytomX Therapeutics
Phase 1/2 Terminated
NCT05265975 2025-06-09
SWATCH
Antengene Corporation
Phase 1/2 Terminated
NCT01251965 2025-06-08
Phase l/II Study of Ruxolitinib for Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05405309 2025-06-03
CORONADO CLL
University of Utah
Phase 1/2 Terminated
NCT01350258 2025-05-31
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Phase 1/2 Terminated
NCT02953509 2025-05-29
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 1/2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03576547 2025-05-08
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03492125 2025-04-10
A Study Of The Selective PKC-β Inhibitor MS- 553
MingSight Pharmaceuticals, Inc
Phase 1/2 Terminated
NCT05296525 2025-03-25
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Gamida Cell ltd
Phase 1/2 Terminated
NCT04419389 2025-03-17
R/R
Aprea Therapeutics
Phase 1/2 Terminated
NCT04718675 2025-02-17
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
Kronos Bio
Phase 1/2 Terminated
NCT05348889 2025-02-13
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
Chimagen Biosciences, Ltd
Phase 1/2 Terminated
NCT04517435 2025-02-07
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Terminated
NCT04029688 2024-12-20
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated
NCT05588440 2024-12-05
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Oncternal Therapeutics, Inc
Phase 1/2 Terminated
NCT03648372 2024-11-19
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Takeda
Phase 1/2 Terminated
NCT04358458 2024-10-24
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Genmab
Phase 1/2 Terminated
NCT05315713 2024-10-04
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1/2 Terminated
NCT01998035 2024-08-22
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT03743246 2024-08-15
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
Phase 1/2 Terminated
NCT04676087 2024-08-13
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Emory University
Phase 1/2 Terminated
NCT02091063 2024-08-06
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT00522990 2024-08-02
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Astex Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT03323398 2024-07-31
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
Phase 1/2 Terminated
NCT04082936 2024-07-24
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
IGM Biosciences, Inc.
Phase 1/2 Terminated
NCT05360238 2024-07-22
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Mustang Bio
Phase 1/2 Terminated